Movement Alert｜DUALITYBIO-B falls 5.37% in Regular Trading, clinical data concerns outweighed buyback and chairman stake increase

On November 3, DUALITYBIO-B fell 5.37% in Regular Trading, trading near HK$100.0, with turnover of HK$7.47 million.

The latest market catalyst points to renewed pressure from the company’s Phase 3 DB-1303 data, even after DUALITYBIO-B disclosed a HK$0.99 million buyback of 10,000 shares on November 2 and recent chairman on-market purchases.

Company disclosures show the November 2 repurchase was executed at HK$98.55 to HK$99.60 per share and the shares were held as treasury stock. Separately, the chairman bought 10,000 shares on October 30 at about HK$105.72 per share, lifting his stake to 17.5%. However, investor focus has remained on the October 26 Phase 3 update for trastuzumab pamirtecan, where the study met its primary endpoint but showed only a statistically significant yet modest progression-free survival improvement, while interstitial lung disease incidence was higher than in prior studies. That combination appears to have kept efficacy and safety expectations under reassessment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)